Cervical cancer

Lancet

Volumn 361, Issue 9376, 2003, Pages 2217-2225

  Waggoner, Steven E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

BLADDER DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNE SYSTEM; INFERTILITY; LYMPHEDEMA; MENOPAUSE; MORBIDITY; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEXUAL DYSFUNCTION; SMOKING; UTERINE CERVIX CARCINOMA;

EID: 0037830009     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13778-6     Document Type: Conference Paper

References (92)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, vol VII. International Agency for Research on Cancer, Scientific Publications number 143. Lyon: IARC, 1997.
2. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-24.
3. Sung H., Kearney K.A., Miller M., Kinney W., Sawaya G.F., Hiatt R.A. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 88:2000;2283-2289.
4. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
5. Chichareon S., Herrero R., Munoz N., et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst. 90:1998;50-56.
6. Ngelangel C., Munoz N., Bosch F.X., et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst. 90:1998;43-49.
7. Koutsky L.A., Holmes K.K., Critchlow C.W., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 327:1992;1272.
8. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
9. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
10. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
11. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:1989;4099-4105.
12. Chellappan S., Kraus V.B., Kroger B., et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between the transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA. 89:1992;4549-4553.
13. Stoppler M.C., Ching K., Stoppler H., Clancy K., Schlegel R., Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol. 70:1996;6987-6993.
14. Berumen J., Ordonez R.M., Lazcano E., et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 93:2001;1325-1330.
15. Kjellberg L., Hallmans G., Ahren A.M., et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 82:2000;1332-1338.
16. Daly S.F., Doyle M., English J., Turner M., Clinch J., Prendiville W. Can the number of cigarettes smoked predict high-grade cervical intraepithelial neoplasia among women with mildly abnormal cervical smears? Am J Obstet Gynecol. 179:1998;399-402.
17. Slattery M.L., Robison L.M., Schuman K.L., et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA. 261:1989;1593-1598.
18. Prokopczyk B., Cox J., Hu P., Hoffman D., El-Bayoumy K., Waggoner S. Identification of tobacco-specific carcinogens in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst. 89:1997;868-873.
19. Melikian A.A., Sun P., Prokopczyk B., et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett. 146:1999;127-134.
20. Wilczynski S.P., Bergen S., Walker J., Liao S.Y., Pearlman L.F. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol. 19:1988;697-704.
21. Johnson T.L., Kim W., Plieth D.A., Sarkar F.H. Detection of HPV 16/18 DNA in cervical adenocarcinoma using polymerase chain reaction (PCR) methodology. Mod Pathol. 5:1992;35-40.
22. Noller K.L., Decker D.G., Lanier A.P., Kurland L.T. Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens. Mayo Clin Proc. 47:1972;629-630.
23. Grigsby P.W., Siegel B.A., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 19:2001;3745-3749.
24. Wagenaar H.C., Trimbos J.B., Postema S., et al. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol. 82:2001;474-482.
25. Hacker N.F., Wain G.V., Nicklin J.L. Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer. 5:1995;250-256.
26. Potish R.A., Downey G.O., Adcock L.L., Prem K.A., Twiggs L.B. The role of surgical debulking in cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 17:1989;979-984.
27. Kim P.Y., Monk B.J., Chabra S., et al. Cervical cancer with paraaortic metastases: significance of residual paraaortic disease after surgical staging. Gynecol Oncol. 69:1998;243-247.
28. Tanaka Y., Sawada S., Murata T. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol. 23:1984;455-459.
29. Tsai C.S., Lai C.H., Wang C.C., et al. The prognostic factors for patients with earyly cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol. 75:1999;328-333.
30. Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 38:1990;352-357.
31. Perez C.A., Grigsby P.W., Chao K.S., Mutch D.G., Lockett M.A. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys. 41:1998;301-317.
32. Benedet J., Odicino F., Maisonneuve P., et al. Carcinoma of the cervix uteri: FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 3:1998;5-34.
33. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol. 28:(suppl 8):2001;60-65.
34. Grisaru D., Covens A., Chapman B., et al. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer. 92:2001;2999-3004.
35. Maiman M., Fruchter R.G., Guy L. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer. 71:1991;402-406.
36. Tseng C.J., Horng S.G., Soong Y.K., Hsueh S., Hsieh C.H., Lin H.W. Conservative conization for microinvasive carcinoma of the cervix. Am J Obstet Gynecol. 176:1997;1009-1010.
37. Creasman W.T. Stage IA cancer of the cervix: finally some resolution of definition and treatment? Gynecol Oncol. 74:1999;163-164.
38. Creasman W.T., Zaino R.J., Major F.J., DiSaia P.J., Hatch K.D., Homesley H.D. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 178:1998;62-65.
39. Jones W.B., Mercer G.O., Lewis J.L., Rubin S.C., Hoskins W.J. Early invasive carcinoma of the cervix. Gynecol Oncol. 51:1993;26-32.
40. Dargent D., Martin X., Sacchetoni A., Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer. 88:2000;1877-1882.
41. Shepherd J.H., Crawford R., Oram D. Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer. Br J Obstet Gynaecol. 105:1998;912-916.
42. Covens A., Shaw P., Murphy J., et al. Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix? Cancer. 86:1999;2273-2279.
43. Ayhan A., Tuncer Z.S., Kucukali T., Tuna T., Enunlu T. Correlation between pathological risk factors and pelvic lymph node metastases in stage I squamous carcinoma of the cervix: a multivariate analysis of 194 cases. J Surg Oncol. 48:1991;207-209.
44. Gauthier P., Gore I., Shingleton H.M., Soong S.J., Orr J.W. Jr, Hatch K.D. Identification of histopathologic risk groups in stage IB squamous cell carcinoma of the cervix. Obstet Gynecol. 66:1985;569.
45. Roman L.D., Felix J.C., Muderspach L.I., et al. Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. Gynecol Oncol. 68:1998;220-225.
46. Covens A., Kirby J., Shaw P., Chapman W., Franseen E. Prognostic factors for relapse and pelvic node metastasis in early stage I adenocarcinoma of the cervix. Gynecol Oncol. 74:1999;423-427.
47. Schorge J.O., Lee K.R., Sheets E.E. Prospective management of stage IA1 cervical adenocarcinoma by conization alone to preserve fertility: a preliminary report. Gynecol Oncol. 78:2000;217-220.
48. Boyce C., Fruchter R., Nicastri A. Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol. 12:1981;154.
49. Potter M.E., Alvarez R.D., Shingleton H.M., Soong S.J., Hatch K.D. Early invasive cervical cancer with pelvic lymph node involvement: to complete or not to complete radical hysterectomy? Gynecol Oncol. 37:1990;78.
50. Magrina J.F.m, Goodrich M.A., Weaver A.L., Podratz K.C. Modified radical hysterectomy: morbidity and mortality. Gynecol Oncol. 59:1995;277-282.
51. Fotiou S., Tserkezoglou A., Hatzieleftheriou G., Apostolikas N. Class III vs class II radical hysterectomy in stage IB cervical carcinoma: a comparison on morbidity and survival. Int J Gynecol Cancer. 7:1997;117-121.
52. Landoni F., Maneo A., Cormio G., et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol. 80:2001;3-12.
53. Delgado G. Stage IB squamous cancer of the cervix: the choice of treatment. Obstet Gynecol Surv. 33:1997;173-183.
54. Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 73:1999;177-183.
55. Morrow CP (moderator). Is pelvic radiation beneficial in the postoperative management of stage IB squamous cell carcinoma of the cervix with pelvic lymph node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? A report from the Presidential Panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 1980; 10: 105-10.
56. Kinney W.K., Alvarez R.D., Reid G.C., et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched case-control study. Gynecol Oncol. 34:1989;258-262.
57. Peters W.A. III, Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18:2000;1606-1613.
58. Petereit D.G., Sarkaria J.N., Potter D.M., Schink J.M. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence-the University of Wisconsin experience. Int J Radiat Oncol Biol Phys. 45:1999;1267-1274.
59. Hoskins WJ, Perez CA, Young RC, eds. Biologic and physical aspects of radiation oncology. In: Perez CA, Hall EJ, Purdy JA, Williamson J, eds. Principles and practice of gynecologic oncology, 2nd edn. Philadelphia: Lippincott, Williams, and Wilkins, 1997.
60. Perez C.A., Breaux S., Madoc-Jones H., Camel H.M., Purdy J.A., Walz B.J. Radiation therapy alone in the treatment of carcinoma of the uteirne cervix. Cancer. 54:1984;235-246.
61. Perez C.A., Grigsby P.W., Castro-Vita H., Lockett M.A. Carcinoma of the uterine cervix. I. Impact of prolongation of treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 32:1995;1275-1288.
62. Hopkins M.P., Morley G.W. Stage IB squamous cell carcinoma of the cervix: clinicopathologic features related to survival. Am J Obstet Gynecol. 164:1991;1520-1527.
63. Homesely H.D., Raben M., Blake D.D., et al. Relationship of lesion size to survival in patients with stage IB squamous cell carcinoma of the cervix uteri treated by radiation therapy. Surg Gynecol Obstet. 150:1980;529-531.
64. Monk B.J., Cha D.S., Walker J.L., et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol. 54:1994;4-9.
65. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet. 350:1997;535-540.
66. Landoni F., Maneo A., Cormio G., et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol. 80:2001;3-12.
67. O'Quinn A., Fletcher G., Wharton J. Guidelines for conservative hysterectomy after irradiation. Gynecol Oncol. 9:1980;68-79.
68. Rutledge F., Wharton J., Fletcher G. Clinical studies with adjunctive surgery and irradiation therapy in the treatment of carcinoma of the cervix. Cancer. 38:1976;596-602.
69. Mendenhall W., McCarty P., Morgan L., Chafe W., Million P. Stage IB-IIA-B carcinoma of the intact uterine cervix greater than or equal to 6 cm in diameter: is adjuvant extrafascial hysterectomy beneficial? Int J Radiat Oncol Biol Phys. 21:1991;899-904.
70. Perez C.A., Kao M.S. Radiation therapy alone or combined with surgery in treatment of barrel-shaped carcinoma of the uterine cervix (stage IB, IIA, IIB). Int J Radiat Oncol Biol Phys. 11:1985;1903-1909.
71. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1999;1154-1161.
72. Keys HM, Hornback N, Okagaki T, Stehman FB. Treatment of patients with sub-optimal ("bulky") stage IB carcinoma of the cervix: a randomized comparison of of radiation therapy versus radiation therapy plus adjuvant extrafascial hysterectomy (GOG # 71, RTOG # 84-22). New York. American Radium Society, 1997 (abstr).
73. Bloss J.D., Lucci J.A., DiSaia P.J., et al. A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Gynecol Oncol. 59:1995;105-110.
74. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17:1999;1339-1348.
75. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153.
76. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1999;1137-1143.
77. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 358:2001;781-786.
78. Rotman M., Pajak T.F., Choi K., et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: ten year treatment results of RTOG 79-20. JAMA. 274:1995;387-393.
79. Haie C., Pejovic M.H., Gerbaulet A., et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol. 11:1988;101-112.
80. Mundt A.J., Roeske J.C., Ljan A.E., et al. Initial clinical experience with intensity-modulated whole pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 82:2001;456-463.
81. Portelance L., Chao K.S., Grigsby P.W., Bennet H., Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 51:2001;261-266.
82. Ijaz T., Eifel P.J., Burke T., Oswald M.J. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol. 70:1998;241-246.
83. Coleman R.L., Keeney E.D., Freedman R.S., Burke T.W., Eifel P.J., Rutledge F.N. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 55:1994;29-35.
84. Penalver M.A., Bejany D.E., Averette H.E., Donato D.M., Sevin B., Suarez G. Continent urinary diversion in gynecologic oncology. Gynecol Oncol. 34:1989;274-288.
85. Shingleton H.M., Soong S.J., Gelder M.S., Hatch K.D., Baker V.V., Austin J.M. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol. 73:1989;1027-1034.
86. Park R.C., Thigpen J.T. Chemotherapy in advanced and recurrent cervical cancer. Cancer. 71:1993;1446-1450.
87. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 17:1999;2676-2680.
88. Moore D.H., McQuellon R.P., Blessing J.A., et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix. Gynecol Oncol. 80:2001;276. (abstr).
89. Brader K.R., Morris M., Levenback C., Levy L., Lucas K.R., Gershenson D.M. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 16:1998;1879-1884.
90. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:2002;1645-1651.
91. Schover L.R. Quality counts: the value of women's perceived quality of life after cervical cancer. Gynecol Oncol. 76:2000;3-4.
92. Greimel E., Thiel I., Peintinger F., Cegnar I., Pongratz E. Prospective assessment of quality of life of female cancer patients. Gynecol Oncol. 85:2002;140-147.